Lifeward

What Lifeward does

Lifeward Ltd. (NASDAQ: LFWD), formerly ReWalk Robotics, is a publicly traded medical device company founded in 2001 that develops wearable robotic exoskeletons and rehabilitation technologies for individuals with lower limb disabilities. The company is domiciled in Israel with US headquarters in Marlborough, Massachusetts, a German subsidiary (Lifeward GmbH, Berlin), and a California operation (Lifeward CA, Inc., formerly AlterG), serving patients with spinal cord injuries, stroke, multiple sclerosis, brain injuries, and orthopedic conditions across the United States, Europe, Israel, and select international markets through channel partners.

The company's portfolio comprises four FDA-cleared hardware platforms: the ReWalk Personal Exoskeleton (now in its seventh generation, the first FDA-cleared personal exoskeleton with stair and curb navigation), the AlterG Anti-Gravity Systems (pressurized air-chamber treadmills using NASA-derived Differential Air Pressure technology), the ReStore Exo-Suit (the first FDA-cleared exo-suit for post-stroke gait training), and MYOLYN Functional Electrical Stimulation cycling systems. In early 2026 Lifeward expanded into biotech through the acquisition of Oratech Pharmaceuticals and the clinical-stage Protein Oral Delivery (POD) platform, targeting oral delivery of pharmaceutical proteins currently administered by injection. The company holds ISO 13485 and FDA 21 CFR Part 820 quality system certifications, FDA clearances for each device line, and CE Mark approval for ReWalk 7.

Lifeward monetizes through direct hardware sales to healthcare facilities and qualifying patients, supplemented by a 4% royalty stream from Oramed on ReWalk franchise net sales for up to 10 years. Pricing follows a unit hardware model across product tiers (MyoCycle Home/Pro, AlterG NEO/PRO, ReWalk Personal Exoskeleton). Patient access is facilitated by Medicare, Medicare Advantage plans (Aetna, Humana, UnitedHealthcare covering approximately 16 million lives), VA benefits, and workers' compensation, supported by an in-house reimbursement team. Distribution combines direct enterprise field sales, a network of 300+ certified clinical training partners, exclusive international distributors such as Verita Neuro for Mexico, Thailand, UAE, and Singapore, and direct-to-patient engagement. FY2025 revenue totaled $22.03 million against a net loss of $19.9 million.

Name

Lifeward

Legal name

Lifeward Ltd.

Website

https://golifeward.com

Company type

Public

Founded year

2001

Operating status

Operating

Headcount range

51–100 employees

Short description

Lifeward is a publicly traded medical device company developing FDA-cleared robotic exoskeletons, anti-gravity treadmills, exo-suits, and FES cycling systems for rehabilitation of patients with spinal cord injury, stroke, multiple sclerosis, and orthopedic conditions, distributing through healthcare providers, the VA, and Medicare Advantage payers.

Ownership category

akta.pro rank

Product category

Rehabilitation Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Limb Prosthetics (Upper/Lower Extremity Prosthetic Systems) (HLAHAEAH)

akta.pro secondary industries

Sports & Active Rehabilitation Devices (Adaptive Sports Mobility, Performance Prosthetics) (HLAHAMAJ), Rehabilitation Therapy Equipment (PT/OT Modalities, Exercise & Balance Devices) (HLAHAMAG), Prosthetics/Orthotics Rehab & Amputee Rehabilitation (HSADAIAN)

Keywords

• Wearable robotic exoskeletons
• Rehabilitation medical devices
• Anti-gravity treadmills
• Functional electrical stimulation
• Neurorehabilitation robotics

Headquarters

HQ city

Marlborough

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain, Infrastructure

Revenue model

1. Medical Device Sales: Sale of FDA-cleared medical devices including ReWalk Personal Exoskeleton, AlterG Anti-Gravity Systems, ReStore Exo-Suit, and MyoCycle FES bikes. Devices are sold to healthcare facilities, rehabilitation centers, and directly to qualifying patients with insurance coverage or self-pay arrangements.
2. Clinical Trial Management Services: Oramed retains responsibility for managing and funding the POD clinical program under a clinical trial management agreement, while Lifeward focuses on MedTech profitability
3. Royalty Revenue: Oramed receives 4% royalties on ReWalk franchise net sales for up to 10 years as part of the strategic partnership agreement

Pricing tiers

Go-to-market motion3 records

Distribution channels6 records

Marketing channels7 records

Core offering

Lifeward designs, manufactures, and sells FDA-cleared wearable robotic exoskeletons, soft robotic exo-suits, anti-gravity treadmill systems, and functional electrical stimulation (FES) cycling devices used by individuals with spinal cord injuries, stroke survivors, and other patients requiring physical rehabilitation. The company sells its medical devices to rehabilitation hospitals, clinical training centers, and directly to qualifying patients through insurance coverage including Medicare, Medicare Advantage, VA benefits, and workers' compensation.

Product overview

Lifeward is a diversified biomedical innovation company offering a portfolio of FDA-cleared medical devices for physical rehabilitation. The product portfolio consists of four core product lines: the ReWalk Personal Exoskeleton (wearable robotic exoskeleton for spinal cord injury patients), the AlterG Anti-Gravity Systems (pressurized air treadmills for unweighted training), the MYOLYN FES Cycling systems (functional electrical stimulation bikes), and the ReStore Exo-Suit (exo-suit for post-stroke rehabilitation). In 2026, Lifeward expanded into biotech through the acquisition of Oramed's Protein Oral Delivery (POD) technology. Founded in 2001 (formerly ReWalk Robotics), the company operates in the United States, Israel, and Germany.

Differentiator

Problem solved

Functional benefit

Brands

• ReWalk: FDA-approved personal exoskeleton system for individuals with spinal cord injury
• AlterG
• MYOLYN
• ReStore

Products and services

• ReWalk Personal Exoskeleton A wearable robotic exoskeleton (now in its seventh generation, ReWalk 7) that enables individuals with spinal cord injury to stand upright, walk, turn, and climb/descend stairs through powered hip and knee motion, with crutch-based control, multiple walking speeds, and a companion mobile app for progress tracking.
• AlterG Anti-Gravity Systems Treadmills with pressurized air chambers using NASA Differential Air Pressure (DAP) technology to reduce gravitational load in precise 1% increments, enabling patients and athletes to move unrestricted and pain-free for rehabilitation and performance training. Includes NEO and PRO series variants.
• MYOLYN FES Cycling Functional Electrical Stimulation (FES) bikes providing therapeutic cycling for clinic and home use. The MyoCycle product line includes Home, Home Plus, Pro, and Pro Plus models with 6- or 10-channel stimulation, cycling and walking gait modes, automated setup, and MyoPortal database access.
• ReStore Exo-Suit A soft robotic gait-training exo-suit using cable-driven actuation designed to promote restoration of functional walking patterns post-stroke; the first FDA-cleared exo-suit for rehabilitating walking ability after stroke.
• Protein Oral Delivery (POD) Technology Clinical-stage protein oral delivery technology acquired from Oramed Pharmaceuticals that enables pharmaceutical proteins (such as insulin) to be delivered as oral pills rather than injections.

Quantifiable outcome

• 800+ ReWalk Personal Exoskeletons in use worldwide
• +3 more outcomes

Named customers8 records

Segments6 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Two partnerships are on record, tiered core and regional.

• Oramed PharmaceuticalscoreStrategic or Co-development Partner · 13 January 2026Transformative strategic partnership involving Lifeward acquiring Oramed's clinical-stage Protein Oral Delivery (POD) technology while Oramed acquires up to 49.99% equity ownership in Lifeward. Investment provides Lifeward access to up to $47 million through equity, convertible notes, milestone-based funding, and warrant coverage. Oramed retains responsibility for managing and funding the POD clinical program including a planned 60-patient U.S. clinical trial for oral insulin candidate ORMD-0801.
• Verita NeuroregionalChannel Partner/ Reseller/ Distributor · 17 December 2025Exclusive distribution partnership for ReWalk Personal Exoskeleton in Mexico, Thailand, and UAE. Verita Neuro will integrate the exoskeleton into its neurorehabilitation programs and leverage its extensive patient database to facilitate clinical adoption.

Scale indicators8 records

Recent moves7 records

Expansion highlights7 records

Direct peers

• Ekso Bionics: Ekso Bionics is the most direct competitor to Lifeward, developing and commercializing powered exoskeletons (EksoNR, Ekso Indego) for stroke, SCI, and neurological rehabilitation in clinical settings. Both companies compete for the same clinician customers and reimbursement pathways.
• Myomo: Myomo develops myoelectric orthotic devices (MyoPro) for individuals with arm paralysis and weakness. While focused on upper extremity, Myomo targets overlapping patient populations (stroke, SCI, MS) and similar payer reimbursement channels as Lifeward.
• CYBERDYNE: CYBERDYNE develops the HAL (Hybrid Assistive Limb) robotic exoskeleton series for medical and industrial applications, including FDA-cleared versions for SCI in the US. CYBERDYNE competes in the same wearable robotic exoskeleton category as Lifeward globally.
• Parker Hannifin (Indego): Parker Hannifin's Indego division produces FDA-cleared powered exoskeletons for SCI and stroke rehabilitation, directly competing with ReWalk Personal Exoskeleton and ReStore Exo-Suit. Both target the same VA, Medicare, and clinical rehabilitation channels.
• Hocoma (DIH Medical): Hocoma, now part of DIH Medical, is a leading provider of robotic rehabilitation devices including the Lokomat gait trainer and Armeo robotic arm. Hocoma competes with Lifeward's ReStore exo-suit and AlterG systems in the clinical neurorehabilitation market.

Emerging players

• Fourier Intelligence: Fourier Intelligence is a Chinese-based rehabilitation robotics company developing exoskeleton and gait training systems. As an emerging global player, it represents competitive pressure particularly in APAC markets and price-sensitive segments that Lifeward addresses.
• Bionik Laboratories: Bionik Laboratories is a smaller rehabilitation robotics company developing the InMotion ARM and InMotion WALK products for upper and lower extremity therapy. As an emerging player, it competes in adjacent portions of the neurorehabilitation robotics market served by Lifeward.

Broad incumbents

• Ottobock: Ottobock is the global leader in prosthetics, orthotics, and exoskeleton technology (including acquired SuitX). While a much larger incumbent, Ottobock competes directly in the wearable robotic exoskeleton space and has the resources to pressure Lifeward's market position.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/ReWalk_Robotics
• YouTubeyoutube.com/channel/UCIZghi_7V9tWDhbu22RlYbg
• Facebookfacebook.com/ReWalk
• LinkedInlinkedin.com/company/rewalk-robotics-inc-
• Instagraminstagram.com/golifeward

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries3 records

Funding overview

Funding rounds21 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lifeward